• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

    31.86 +10.43 (+48.67%)
    Streaming Delayed Price Updated: 11:39 AM EDT, Aug 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 14,932,415
    Open 29.91
    Bid (Size) 31.86 (200)
    Ask (Size) 31.92 (100)
    Prev. Close 21.43
    Today's Range 28.00 - 32.81
    52wk Range 7.630 - 24.60
    Shares Outstanding 67,176,067
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55% ↗
    Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus... 
    Via MarketBeat
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity... 
    Via Benzinga

    Performance

    YTD
    +179.0%
    +179.0%
    1 Month
    +82.6%
    +82.6%
    3 Month
    +147.7%
    +147.7%
    6 Month
    +125.5%
    +125.5%
    1 Year
    +298.7%
    +298.7%

    More News

    Read More
    News headline image
    Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms ↗
    Via Chartmill
    Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data ↗
    Via Chartmill
    News headline image
    Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx (AMLX) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Amylyx Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape ↗
    Via MarketBeat
    News headline image
    Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    What to Know About This Fund's $10 Million Bet on Gold Miners ↗
    Via The Motley Fool
    Topics Economy
    News headline image
    Amylyx Stock: Why the Full Pipeline Story Matters ↗
    Via MarketBeat
    News headline image
    Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus ↗
    Via MarketBeat
    News headline image
    Amylyx (AMLX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
    From Amylyx Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?
    Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market
    What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?
    The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 31.86
    When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 08/18/26 11:39 AM ET
    What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 2.14B
    How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?
    Amylyx Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.